Lupin Launches World's First Fixed-Dose Triple Combination Inhaler for COPD in India
Lupin Ltd 路 Press Release 路 06 Oct 2026, 3:06 pm
Lupin Launches World's First Fixed-Dose Triple Combination Inhaler for COPD in India Lupin Limited launched Formoflo-G MDI on 6th Oct'26, the world鈥檚 first fixed-dose triple-combination metered-dose inhaler for chronic obstructive pulmonary disease (COPD) management, following DCGI approval. The product combines Glycopyrronium Bromide, Formoterol Fumarate, and Fluticasone Propionate into a twice-daily, single-strength inhaler to treat moderate-to-severe COPD. Targeting a domestic patient pool exceeding 55 million individuals, the launch enhances Lupin鈥檚 domestic respiratory portfolio, where it holds the #2 market rank according to IQVIA MAT Mar'26 data.
Original exchange filing (PDF)
More announcements from Lupin Ltd
- Lupin Announces European Launch of Biosimilar Ranibizumab. 路 12 Nov 2026
- Transcript of Q2 FY2027 Earnings Conference Call. 路 07 Nov 2026
- Link of Audio recording of the Earnings Call-Q2 FY27. 路 05 Nov 2026
- Investor Presentation- Q2 FY2027 路 04 Nov 2026
- Lupin Q2 FY2027 Results 路 04 Nov 2026
- Appointment of Mr. Akhil Gupta as an Additional Director (Non-Executive, Independent) effective November 03, 2026 and as an Independent Director for a term of five consecutive years with .... 路 04 Nov 2026
- Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026. 路 04 Nov 2026
- Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026. 路 04 Nov 2026
